Patents
Methods of modulating c-kit tyrosine protein kinase function with indolinone compounds
Patent Number: 7,211,600It is known that tumor stem cells share many properties with non-malignant stem cells, such as expression of CD133. The receptor for stem cell factor, c-kit, is found on numerous types of normal stem cells in addition to hematopoietic stem cells, where it was originally discovered. This current patent discloses a variety of compounds...
Inventors: Lipson; Ken (San Mateo, CA), McMahon; Gerald (Kenwood, CA)
Assignee: Sugen Inc. (South San Francisco, CA)
Date of First Priority Issue: Wednesday December 22nd, 1999
Primitive neural stem cells and method for differentiation of stem cells to neural cells
Patent Number: 7,211,434Generation of neurons and neuronal committed cells from embryonic stem cells has been extensively documented by separation of cells from embryoid bodies. However the generation of embryoid bodies from embryonic stem cells is subject to US patent #"6602711":https://www.stemcellpatents.com/patents-show-373 which is owned by WARF and licensed to Geron. So while the whole world is trying to...
Inventors: Van Der Kooy; Derek (Toronto, Ontario, CA), Tropepe; Vincent (Boston, MA)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday September 29th, 2000
Resorbable extracellular matrix for reconstruction of cartilage
Patent Number: 7,208,177The current patent covers a matrix that is useful for treatment of cartilage injuries. The matrix disclosed is resorbable at a controlled rate and contains collagen II either from autologous, allogeneic, or xenogeneic sources. Specific pore sizes and additives are claimed. The patent is useful for parties seeking methods of introducing cells or growth factors to accelerate cartilage healing...
Inventors: Geistlich; Peter (Stansstad, CH), Schloesser; Lothar (Darmstadt, DE)
Assignee: Ed. Geistlich Soehne AG fuer Chemische Industrie (Wolhusen, CH)
Date of First Priority Issue: Wednesday February 22nd, 1995
Methods for treating disease and forming a supplemented fibrin matrix
Patent Number: 7,208,179The current patent covers various compositions of matter for manufacturing tissue sealants. The sealants covered contain various growth factors, either recombinantly produced and added, or added through activation of cells. The sealants described are potentially synergistic with stem cells for acceleration of wound healing.
Inventors: Drohan; William N. (Springfield, VA), MacPhee; Martin James (Gaithersburg, MD), Hollinger; Jeffrey O. (Gibsonia, PA)
Assignee: The American National Red Cross (Rockville, MD)
Date of First Priority Issue: Tuesday November 27th, 1990
Nucleic acids and protein variants of hG-CSF with granulopoietic activity
Patent Number: 7,208,473This patent covers a strange modified G-CSF protein that is not G-CSF but possesses properties of G-CSF. It seems really interesting for easy commercialization...especially for "biogeneric" G-CSF.
Inventors: Dahiyat; Bassil I. (Alta Dena, CA), Luo; Peizhi (Sunnyvale, CA)
Assignee: Xencor, Inc. (Monrovia, CA)
Date of First Priority Issue: Wednesday January 6th, 1999
Genome mutation by intron insertion into an embryonic stem cell genome
Patent Number: 7,205,148Genetic manipulation of ES cells provides a powerful method for developing unique cell line models of various human diseases. More clinically applicable is the possibility of specifically producing mutations in genes that elicit rejection of ES cells, so as to generate "universal donor" stem cells. This patent teaches ways of generating mutations in exons of genes in ES cells by introduction...
Inventors: Economides; Aris N. (Tarrytown, NY), Valenzuela; David M. (Yorktown Heights, NY), Davis; Samuel (New York, NY), Yancopoulos; George (Yorktown Heights, NY)
Assignee: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
Date of First Priority Issue: Thursday June 10th, 2004
Generation of hematopoietic cells from multipotent neural stem cells
Patent Number: 7,204,979The concept of cellular transdifferentiation has come under much attack in the last few years. For example, some authors believe that transdifferentiation can be explained by cellular fusion in in vivo systems, and by non-physiological, contrived, in vitro systems. This patent covers the generation of hematopoietic stem cells from multipotent neural stem cells by the administration of the...
Inventors: Bjornson; Christopher R. (Seattle, WA), Rietze; Rod L. (Brunswick, AU), Reynolds; Brent A. (Saltspring, CA), Vescovi; Angelo L. (Milan, IT)
Assignee: Neurospheres Holdings Ltd. (Alberta, CA)
Date of First Priority Issue: Monday September 29th, 1997
Substituted 5-alkynyl pyrimidines having neurotrophic activity
Patent Number: 7,205,297This patent discloses a series of companies that are substituted 5-alkynyl pyrimidines with nerve growth factor-like (NGF) activity for treatment of neurological disorders. Essentially, the data the inventors disclosed in the patent is that these compounds they generated can induce promotion of neurite outgrowth and elevation of choline acetyltransferase in the PC12 cell line. The...
Inventors: Beauchamp; Lilia M. (Raleigh, NC), Krenitsky; Thomas A. (Chapel Hill, NC), Kelley; James L. (Raleigh, NC)
Assignee: Krenitsky Pharmaceuticals, Inc. (Durham, NC)
Date of First Priority Issue: Monday July 24th, 2000
Method for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway
Patent Number: 7,202,080This patent teaches methods of generating pancreatic-like cells for either hematopoietic stem cells or mesenchymal stem cells. The patent covers the use of specific tissue culture cocktail which contains various growth factors, for inducing expression of pancreatic genes in cells of CD34 or mesenchymal lineage. The patent does not document in vivo activity of the cells generated by these...
Inventors: Ramiya; Vijaykumar (Gainesville, FL), Clark; Amy (Gainesville, FL)
Assignee: Ixion Biotechnology, Inc. (Alachua, FL)
Date of First Priority Issue: Thursday March 29th, 2001
Materials and methods for management of hyperacute rejection in human xenotransplantation
Patent Number: 7,201,899Xenogeneic transplants from lower animals to humans are prevented in part by the hyper-rejection phenomena which ensues as a result of preformed antibodies against alpha-gal epitopes. Alpha-gal epiptopes are generated as a result of activity of the enzyme alpha.-1,3 galactosyltransferase. This patent covers cells, including ES cells, for generation of knockout pigs or organs which lack the...
Inventors: d'Apice; Anthony J. F. (Balwyn, AU), Pearse; Martin J. (Mordialloc, AU), Robins; Allan J. (Waterloo Corner, AU), Crawford; Robert J. (West Lake Shores, AU), Rathjen; Peter D. (Blackwood, AU)
Assignee: BresaGen Limited (Thebarton SA, AU)
Date of First Priority Issue: Thursday January 27th, 1994